BioVie Inc (BIVI)

[someconcerns]

NanoAntibiotics Changes Name to BioVie and Welcomes Dr. Patrick Yeramian to Clinical Team
BY Market Wire
— 8:00 AM ET 08/22/2016

BEVERLY, MA -- (Marketwired) -- 08/22/16 -- BioVie Inc. ( BIVI) (the "Company," formerly NanoAntibiotics, Inc.), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced today that shareholders have approved changing the company name to BioVie Inc. ( BIVI) The Company's stock will now trade under the symbol "BIVI." More information is available at www.biovieinc.com.

BioVie ( BIVI) also welcomed Dr. Patrick Yeramian as consultant Medical Director to guide the clinical development program for the Company's new drug candidate, BIV201. This novel therapeutic is based on proprietary CIPT Technology and is being developed to treat ascites due to liver cirrhosis, a life-threatening condition. "Dr. Yeramian's broad experience, proven track record, and professional connections make him a great addition to our team. He has already made important contributions to our investigational new drug (IND) application which is progressing ahead of schedule. His expertise will be invaluable for clinical trial execution," commented CEO Jonathan Adams.

Prior to joining the BioVie ( BIVI) team, Dr. Yeramian worked with the Company's regulatory expert, Stacy Suberg, Ph.D. "I've worked with Stacy on successful clinical trials in the past. I look forward to working with her again, and the other members of the BioVie ( BIVI) team. The therapeutic concept behind BIV201 is based on compelling data, which spurred my interest in the clinical program," commented Dr. Yeramian.

Dr. Yeramian brings three decades of experience in research and drug and medical device development to BioVie's ( BIVI ) management team. He has served as a medical director for multiple organizations including Searle Pharmaceuticals (now Pfizer), the Vaccine and Gene Therapy Institute of Florida, and TapImmune Inc. During his career, he has helped companies secure over $25 million in grants and awards, filed more than 20 investigational new drug and device applications (INDs/CTX/CTAs), and won regulatory approvals for five new drugs and devices.

BioVie's ( BIVI) immediate goal for BIV201 is to commence a clinical trial as early as 2017, contingent on FDA acceptance of an Investigational New Drug ("IND") application, which is currently in development. For more information, please visit our website www.biovieinc.com.

About Liver Cirrhosis and Ascites

About one million Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th-leading cause of death due to disease in the US, killing an estimated 27,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity. Ascites is a common complication of advanced liver cirrhosis. With no medications approved by the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients may fail to respond to treatment as ascites worsens. This unfavorable prognosis represents a critical unmet medical need. US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.

About BioVie ( BIVI) (formerly NanoAntibiotics)

BioVie Inc. ( BIVI) is a development-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on commercializing BIV201, a novel approach to the treatment of ascites due to liver cirrhosis. In early 2016 the Company held a pre-investigational new drug ("pre-IND") meeting with the FDA, which provided guidance for an IND submission. The Company's new drug candidate could potentially commence US clinical trials as early as 2017.